Designing the molecular future

Designing the molecular future

Gisbert Schneider

Abstract Approximately 25 years ago the first computer applications were conceived for the purpose of automated 'de novo' drug design, prominent pioneering tools being ALADDIN, CAVEAT, GENOA, and DYLOMMS. Many of these early concepts were enabled by innovative techniques for ligand-receptor interaction modeling like GRID, MCSS, DOCK, and CoMFA, which still provide the theoretical framework for several more recently developed molecular design algorithms. After a first wave of software tools and groundbreaking applications in the 1990s—expressly GROW, GrowMol, LEGEND, and LUDI representing some of the key players—we are currently witnessing a renewed strong interest in this field. Innovative ideas for both receptor and ligand-based drug design have recently been published. We here provide a personal perspective on the evolution of de novo design, highlighting some of the historic achievements as well as possible future developments of this exciting field of research, which combines multiple scientific disciplines and is, like few other areas in chemistry, subject to continuous enthusiastic discussion and compassionate dispute.

Keywords Drug design · Computational chemistry · Fragment-based design · De novo design

G. Schneider (✉)
Department of Chemistry and Applied Biosciences,
Institute of Pharmaceutical Sciences, Swiss Federal Institute
of Technology (ETH), Wolfgang-Pauli-Str. 10, 8093 Zurich,
Switzerland
e-mail: gisbert.schneider@pharma.ethz.ch

Introducton

Approximately 25 years ago the first computer applications were conceived for the purpose of automated "de novo" drug design [1–4], prominent pioneering tools being ALADDIN [5], CAVEAT [6, 7], GENOA [8], and DYLOMMS [9]. Many of these early concepts were enabled by innovative techniques for ligand-receptor interaction modeling like GRID [10], MCSS [11], DOCK [12], and CoMFA [13], which still provide the theoretical framework for several more recently developed molecular design algorithms. After a first wave of software tools and groundbreaking applications in the 1990s [14–18]—expressly GROW [19], GrowMol [20], LEGEND [21, 22], and LUDI [23, 24] representing some of the key players—we are currently witnessing a renewed strong interest in this field. Innovative ideas for both receptor- and ligand-based drug design have recently been published [25, 26]. We here provide a personal perspective on the evolution of de novo design, highlighting some of the historic achievements as well as possible future developments of this exciting field of research, which combines multiple scientific disciplines and is, like few other areas in chemistry, subject to continuous enthusiastic discussion and compassionate dispute.

Broadly speaking, the main scientific challenges for de novo drug design are compound scoring (activity prediction, $\Delta G°$ estimation), sampling (on-the-fly compound assembly and navigation in search space), and the synthetic accessibility of the designs [27]. In their pioneering study from 1991 [19], Moon and Howe argued that: "Given detailed structural knowledge of the target receptor, it should be possible to construct a model of a potential ligand, by algorithmic connection of small molecular fragments, that will exhibit the desired structural and

electrostatic complementarity with the receptor". At the time, searching the space of candidate compounds was considered the most critical issue of the design process, and molecular fragments as building blocks were primarily used to obtain a manageable search space. This was one reason for choosing peptides and peptide-mimetics as a preferred molecule class for exploration. Among the various algorithms that have been employed for de novo design ever since, the methods for navigation in chemical space probably have diversified the most, ranging from exhaustive product enumeration and deterministic combinatorial approaches to stochastic sampling by evolutionary algorithms and particle swarms, simulated annealing, and Markov chains, to name just some of the prominent examples [26]. By method transfer the field has massively benefited from parallel developments in computer science and engineering. Today, visualization of the multi-objective compound optimization progress and online structure–activity landscape modeling can be used to observe and potentially prevent premature convergence or misguided design runs [28–30]. It is fair to say that one might consider the task of chemical space navigation solved. With the first structure-based de novo design study published in 1976 [31, 32], this is mirrored in the continuously increasing

number of successful compound designs that have been published ever since (Fig. 1).

With few exceptions, the early design methods relied on static X-ray structures providing the essential structural and pharmacophoric feature constraints for in situ ligand assembly. Evidently, rigid models of ligand-accommodating receptor cavities cannot account for induced or flexible fit phenomena that may be observed upon fragment binding, which certainly has contributed to a somewhat curbed enthusiasm and acceptance of de novo design by the medicinal chemistry community at the time. Some of the current molecular design tools explicitly allow for molecular flexibility, albeit sometimes at the price of strongly increased needs for computation time. Unrealistic CPU time requirement has been an argument repeatedly put forward by molecular designers when applications were unsuccessful or too demanding challenges were posed. While this argument might have been acceptable in the past, it may no longer be justified in light of continuously increasing capacity of modern computers. From a technical point of view, it seems realistic that GPU computing, cloud computing and other massively distributed hardware solutions will provide the necessary technological framework enabling sustained progress in de novo design. Still, we must not forget that our


Fig. 1 Selected computationally de novo designed or motivated compounds that were synthesized and successfully tested for bioactivity. **1**: FKBP12 inhibitor [51]; **2**: HIV-1 protease inhibitor [52]; **3**: thrombin inhibitor [53]; **4**: pepsin inhibitor [54]; **5**: DNA gyrase inhibitor [55]; **6**: Kv1.5 potassium channel blocker [56]; **7**: CDK4 inhibitor [57, 58]; **8**: CYP51 inhibitor [59]; **9**: HIV-1 reverse transcriptase inhibitor [34]; **10**: factor Xa inhibitor [60]; **11**: HIV-1 protease inhibitor [61]; **12**: DHODH inhibitor [62]; **13**: HIV-1 reverse transcriptase inhibitor [63]; **14**: Tat-TAR interaction inhibitor [64]; **15**: Estrogen receptor ligand [65]; **16**: Cdc25B phosphatase inhibitor [66]; **17**: CB1 inverse agonist [40]; **18**: Plk1 type II inhibitor [67]

understanding of the physical forces governing ligand-receptor interaction is incomplete, and gaining a decimal point in computational precision is meaningless if insufficient models are used.

With the advent of reaction-driven compound fragmentation and assembly techniques (e.g. RECAP [33], virtual organic synthesis approaches like SYNOPSIS [34] or TOPAS [35]) and fast substructure-based prediction of "complexity" the issue of synthetic feasibility has been partially addressed. Despite several convincing applications, the accurate computer-based assessment of context-dependent building block reactivity still remains profoundly challenging—in particular when rapid estimations for high-throughput applications are mandatory like in de novo compound construction.

The great importance of using a suitable set of fragments for virtual compound generation is highlighted exemplarily by three selected case studies. The first describes the design of novel inhibitors of hepatitis C virus (HCV) helicase. Brancale and coworkers equipped the receptor-based de novo design software LigBuilder [36] with two different sets of molecular building blocks, which resulted in the initial designs A and B, respectively (Fig. 2) [37]. It is evident that the highly complex compound A is an attempt to fill the complete binding site, which most likely is a consequence of poor scoring as larger compounds often yield better scores. To some degree, such complex structural suggestions produced by de novo design software have hampered acceptance of computer-based de novo

design by medicinal chemists in the past. Design B—despite its nondrug-like structure—might be considered as a prototype ligand of HCV helicase, which was actually successfully converted into the chemically feasible inhibitor **19** ($IC_{50} = 260$ nM). Derivative molecules with such changes still fit the in silico models but have improved synthetic accessibility and more desirable physicochemical properties.

A conceptually related ligand-based approach has been presented by Feher et al. who used the Evolutionary Algorithm Inventor (EAI) software together with a topological pharmacophore model for generating compound modifications of inhibitors of the gonadotropin releasing hormone (GnRH) receptor [38]. Basically, the software suggested scaffolds and their decoration by suitable side-chains that matched reference pharmacophore models. Several potent combinatorial variations were synthesized, one of which (compound **20**) exhibited strong antagonistic activity ($K_i = 50$ nM) on the GnRH receptor (Fig. 3) [39]. Tight interaction with medicinal chemists proved to be essential for post hoc candidate selection and building block prioritization.

A third example of compound optimization from a de novo designed prototype to a potent lead structure is presented in Fig. 4. The software TOPAS produced a small series of structural suggestions that were further optimized as potent inverse agonists of cannabinoid receptor 1 (CB1) [40]. A single known reference compound served as a template for fragment-based virtual ligand assembly, guided by a topological pharmacophore model (CATS) [41]. One of the initial designs (**21**) had poor activity ($K_i = 1,500$ nM) but was chosen for subsequent optimization

Fig. 2 De novo designed inhibitors of hepatitis C virus (HCV) helicase. Designs A and B were suggested by the software using different sets of fragments for compound generation. Bioactive compound **19** was developed from Design B as a starting point for optimization


Fig. 3 Combinatorial design of GnRH receptor ligands. Several potent hits were obtained by in silico side-chain optimization

Fig. 4 De novo designed hCB1 inverse agonists. The original design (**21**) was step-wise optimized to become a potent lead structure with desired in vivo efficacy

through iterative modeling, synthesis, and testing, which via intermediate compound **22** ($K_i = 13$ nM) eventually led to the benzodioxole **23** ($K_i = 4$ nM) exhibiting desired in vivo efficacy [42].

These selected examples confirm that profound chemical understanding is essential for successful application of computer-based de novo design tools. One cannot expect that these software tools deliver potent leads from scratch. Future drug design tools should incorporate as much medicinal chemistry knowledge as possible to facilitate candidate selection and increase their acceptance and utilization for drug discovery.

The greatest remaining challenge is activity prediction—not just for individual targets but also whole target panels aiming at polypharmacology predictions guiding automated computer-based molecular design. Since the early days fragment growing and linking has become a recurring scheme pursued by the majority of de novo design approaches. When fragment contributions to the free energy of ligand-receptor binding are of an approximately additive enthalpic nature, even computationally demanding methods may be employed for energy estimation. Despite its appeal building block additivity cannot be assumed a priori. Irrespective of such considerations, we are still far from being able to reliably estimate entropic contributions to ligand-receptor complex formation. With few exceptions, scoring of de novo designed compounds usually ignores or

explicitly avoids attempts of entropy calculation. Here, we see a massive demand for innovative concepts and approaches before significant progress will be possible for de novo design. Similar to structure sampling, the field might benefit from intensified crosstalk and interaction between drug designers, theoretical chemists and physicists.

"Top-down" machine learning models complement the "bottom-up" scoring concepts and have found productive application in de novo design software. For example, different types of artificial neural networks and kernel-based regression models have replaced the early QSAR models. A particular appeal lies in their speed of calculation and adaptability to new data, without the need for explicit energy computation. Possibly the machine-learning paradigm offers a temporary solution to the scoring problem, by providing "knowledge-based", target-specific models instead of "global" energy computation. A major limitation of these methods is their need for training data, which are available in great amounts for massively researched targets only. The most simplistic approach to compound scoring is offered by methods based on chemical similarity. Here, the objective is to maximize similarity between the de novo designs and reference compound(s) with known activity. This technique may be considered as similarity searching in virtual chemical space. Again, the concept does not apply to novel targets or pockets, but has been successfully employed for the purpose of scaffold-hopping and bioisosteric replacement.

We expect immediate progress for receptor-based de novo design from a combination of flexible pocket models with advanced methods for shape and pharmacophore matching. Such a scoring scheme would include extended pharmacophoric features allowing, e.g., for "strong", "medium" and "weak" hydrogen bridges, better consideration of arene–arene interactions and geometries, as well as explicit solvent molecules, and would allow for moderate pocket and ligand adaptation during the actual ligand construction, thereby possibly avoiding artifact ligand poses [43]. With continuously better scoring functions available, de novo designed compounds will have a greater chance of exhibiting the desired activity and property profile, and due to increased "chemical attractiveness" getting accepted for synthesis.

With high-throughput screening and fragment-based approaches fuelling today's drug discovery pipelines, computer-assisted de novo design plays an increasing role in this game [25, 44, 45]. It will be most interesting to see how this situation will develop during the next decade [46–48]. Structural novelty combined with synthetic feasibility might be more important for a de novo design than actual bioactivity, which can often be increased by means of medicinal chemistry [49]. In 1987, Sheridan et al. wrote [50]: "Only a few novel bond 'frameworks' in which important

pharmacophore atoms are held in the proper arrangement need to be found to suggest new areas for drug design and synthesis." This statement is true today as it was in the early days of computer-based drug design. The primary aim of de novo design tools is to fuel the creativity of chemists by making surprising and innovative suggestions.

References

1. Gund P, Wipke WT, Langridge R (1974) Computer searching of a molecular structure file for pharmacophoric patterns. Comput Chem Res Educ Technol 3:5–21
2. Martin YC, Bures MG, Willett P (1990) Searching databases of three-dimensional structures. In: Lipkowitz K, Boyd D (eds) Reviews in computational chemistry, vol 1. VCH, Weinheim, pp 213–263
3. Sheridan RP, Venkataraghavan R (1987) Designing novel nicotinic agonists by searching a database of molecular shapes. J Comput Aided Mol Des 1:243–256
4. Lewis RA, Dean PM (1989) Automated site-directed drug design: the formation of molecular templates in primary structure generation. Proc R Soc Lond B 236:141–162
5. VanDrie JH, Weininger D, Martin YC (1989) ALADDIN: an integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures. J Comput Aided Mol Des 3:225–240
6. Bartlett PA, Shea GT, Telfer SJ, Waterman S (1989) CAVEAT: a program to facilitate the structure-derived design of biologically active molecules. In: Roberts SM (ed) Molecular recognition in chemical and biological problems, vol 78. Spec Publ R Soc Chem, Cambridge, pp 182–196
7. Lauri G, Bartlett PA (1994) CAVEAT: a program to facilitate the design of organic molecules. J Comput Aided Mol Des 8:51–66
8. Carhart RE, Smith DH, Gray NAB, Nourse JG, Djerassi C (1981) GENOA: a computer program for structure elucidation utilizing overlapping and alternative substructures. J Org Chem 46:1708–1718
9. Wise M, Cramer RD, Smith D, Exman I (1983) Progress in three-dimensional drug design: the use of real time color graphics and computer postulation of bioactive molecules in DYLOMMS. In: Dearden JC (ed) Quantitative approaches to drug design. Elsevier, Amsterdam, pp 145–146
10. Goodford PJ (1995) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849–857
11. Miranker A, Karplus M (1991) Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 11:29–34
12. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE (1982) A geometric approach to macromolecule-ligand interactions. J Mol Biol 161:269–288
13. Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967
14. Jackson RC (1995) Update on computer-aided drug design. Curr Opin Biotechnol 6:646–651
15. Böhm HJ (1996) Current computational tools for de novo ligand design. Curr Opin Biotechnol 7:433–436
16. Bohacek RS, McMartin C (1997) Modern computational chemistry and drug discovery: structure generating programs. Curr Opin Chem Biol 1:157–161
17. Marrone TJ, Briggs JM, McCammon JA (1997) Structure-based drug design: computational advances. Annu Rev Pharmacol Toxicol 37:71–90
18. Kubinyi H (1998) Combinatorial and computational approaches in structure-based drug design. Curr Opin Drug Discov Devel 1:16–27
19. Moon JB, Howe WJ (1991) Computer design of bioactive molecules: a method for receptor-based de novo ligand design. Proteins 11:314–328
20. Bohacek RS, McMartin C (1994) Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth. J Am Chem Soc 116:5560–5571
21. Nishibata Y, Itai A (1991) Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation. Tetrahedron 47:8985–8990
22. Nishibata Y, Itai A (1993) Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation. J Med Chem 36:2921–2928
23. Böhm HJ (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 6:61–78
24. Böhm HJ (1992) LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J Comput Aided Mol Des 6:593–606
25. Loving K, Alberts I, Sherman W (2010) Computational approaches for fragment-based and de novo design. Curr Top Med Chem 10:14–32
26. Hartenfeller M, Schneider G (2011) Enabling future drug discovery by de novo design. WIREs Comp Mol Sci 1:742–759
27. Schneider G, Fechner U (2005) Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 4:649–663
28. Reutlinger M, Guba W, Martin RE, Alanine AI, Hoffmann T, Klenner A, Hiss JA, Schneider P, Schneider G (2011) Neighborhood-preserving visualization of adaptive structure-activity landscapes: application to drug discovery. Angew Chem Int Ed Engl. doi:10.1002/anie.201105156
29. Schneider G, Hartenfeller M, Reutlinger M, Tanrikulu Y, Proschak E, Schneider P (2009) Voyages to the (un)known: adaptive design of bioactive compounds. Trends Biotechnol 27:18–26
30. Dimova D, Wawer M, Wassermann AM, Bajorath J (2011) Design of multitarget activity landscapes that capture hierarchical activity cliff distributions. J Chem Inf Model 51:258–266
31. Beddell CR, Goodford PJ, Norrington FE, Wilkinson S, Wootton R (1976) Compounds designed to fit a site of known structure in human haemoglobin. Br J Pharmacol 57:201–209
32. Beddell CR, Goodford PJ, Stammers DK, Wootton R (1979) Species differences in the binding of compounds designed to fit a site of known structure in adult human haemoglobin. Br J Pharmacol 65:535–543
33. Lewell XQ, Judd DB, Watson SP, Hann MM (1998) RECAP—retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci 38:511–522
34. Vinkers HM, de Jonge MR, Daeyaert FF, Heeres J, Koymans LM, van Lenthe JH, Lewi PJ, Timmerman H, Van Aken K, Janssen PA (2003) SYNOPSIS: synthesize and optimize system in silico. J Med Chem 46:2765–2773
35. Schneider G, Lee ML, Stahl M, Schneider P (2000) De novo design of molecular architectures by evolutionary assembly of

drug-derived building blocks. J Comput Aided Mol Des 14:487–494

36. Wang R, Gao Y, Lai L (2000) LigBuilder: a multi-purpose program for structure-based drug design. J Mol Model 6:498–516

37. Kandil S, Biondaro S, Vlachakis D, Cummins AC, Coluccia A, Berry C, Leyssen P, Neyts J, Brancale A (2009) Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg Med Chem Lett 19:2935–2937

38. Feher M, Gao Y, Baber JC, Shirley WA, Saunders J (2008) The use of ligand-based de novo design for scaffold hopping and sidechain optimization: two case studies. Bioorg Med Chem 16:422–427

39. Lanier MC, Feher M, Ashweek NJ, Loweth CJ, Rueter JK, Slee DH, Williams JP, Zhu YF, Sullivan SK, Brown MS (2007) Selection, synthesis, and structure-activity relationship of tetra-hydropyrido[4, 3-d]pyrimidine-2, 4-diones as human GnRH receptor antagonists. Bioorg Med Chem 15:5590–5603

40. Rogers-Evans M, Alanine A, Bleicher K, Kube D, Schneider G (2004) Identification of novel cannabinoid receptor ligands via evolutionary de novo design and rapid parallel synthesis. QSAR Comb Sci 26:426–430

41. Schneider G, Neidhart W, Giller T, Schmid G (1999) 'Scaffold-hopping' by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed Engl 38:2894–2896

42. Alig L, Alsenz J, Andjelkovic M, Bendels S, Bénardeau A, Bleicher K, Bourson A, David-Pierson P, Guba W, Hildbrand S, Kube D, Lübbers T, Mayweg AV, Narquizian R, Neidhart W, Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, Röver S, Schneider G, Taylor S, Waldmeier P (2008) Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. J Med Chem 51:2115–2127

43. Bissantz C, Kuhn B, Stahl M (2010) A medicinal chemist's guide to molecular interactions. J Med Chem 53:5061–5084

44. Mauser H, Guba W (2008) Recent developments in de novo design and scaffold hopping. Curr Opin Drug Discov Devel 11:365–374

45. Langdon SR, Ertl P, Brown N (2010) Bioisosteric replacement and scaffold hopping in lead generation and optimization. Mol Inf 29:366–385

46. Bailey D, Brown D (2001) High-throughput chemistry and structure-based design: survival of the smartest. Drug Discov Today 6:57–59

47. Bleicher KH, Böhm HJ, Müller K, Alanine AI (2003) Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2:369–378

48. Schneider G (2010) Virtual screening: an endless staircase? Nat Rev Drug Discov 9:273–276

49. Krüger BA, Dietrich A, Baringhaus KH, Schneider G (2009) Scaffold-hopping potential of fragment-based de novo design: the chances and limits of variation. Comb Chem High Throughput Screen 12:383–396

50. Sheridan RP, Rusinko A III, Nilakantan R, Venkataraghavan R (1989) Searching for pharmacophores in large coordinate data bases and its use in drug design. Proc Natl Acad Sci USA 86:8165–8169

51. Babine RE, Bleckman TM, Kissinger CR, Showalter R, Pelletier LA, Lewis C, Tucker K, Moomaw E, Parge HE, Villafranca JE (1995) Design, synthesis and X-ray crystallographic studies of novel FKBB-12 ligands. Bioorg Med Chem Lett 5:1719–1724

52. Reich SH, Melnick M, Davies JF II, Appelt K, Lewis KK, Fuhry MA, Pino M, Trippe AJ, Nguyen D, Dawson H, Wu BW, Musick L, Kosa M, Kahil D, Webber S, Gehlhaar DK, Andrada D, Shetty B (1995) Protein structure-based design of potent orally bio-available, nonpeptide inhibitors of human immunodeficiency virus protease. Proc Natl Acad Sci USA 92:3298–3302

53. Böhm HJ, Banner DW, Weber L (1999) Combinatorial docking and combinatorial chemistry: design of potent non-peptide thrombin inhibitors. J Comput Aided Mol Des 13:51–56

54. Ripka AS, Satyshur KA, Bohacek RS, Rich DH (2001) Aspartic protease inhibitors designed from computer-generated templates bind as predicted. Org Lett 3:2309–2312

55. Böhm HJ, Boehringer M, Bur D, Gmuender H, Huber W, Klaus W, Kostrewa D, Kuehne H, Luebbers T, Meunier-Keller N, Mueller F (2000) Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 43:2664–2674

56. Schneider G, Clément-Chomienne O, Hilfiger L, Schneider P, Kirsch S, Böhm HJ, Neidhart W (2000) Virtual screening for bioactive molecules by evolutionary de novo design. Angew Chem Int Ed Engl 39:4130–4133

57. Honma T, Hayashi K, Aoyama T, Hashimoto N, Machida T, Fukasawa K, Iwama T, Ikeura C, Ikuta M, Suzuki-Takahashi I, Iwasawa Y, Hayama T, Nishimura S, Morishima H (2001) Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 44:4615–4627

58. Honma T, Yoshizumi T, Hashimoto N, Hayashi K, Kawanishi N, Fukasawa K, Takaki T, Ikeura C, Ikuta M, Suzuki-Takahashi I, Hayama T, Nishimura S, Morishima H (2001) A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J Med Chem 44:4628–4640

59. Ji H, Zhang W, Zhang M, Kudo M, Aoyama Y, Yoshida Y, Sheng C, Song Y, Yang S, Zhou Y, Lü J, Zhu J (2003) Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. J Med Chem 46:474–485

60. Liebeschuetz JW, Jones SD, Morgan PJ, Murray CW, Rimmer AD, Roscoe JM, Waszkowycz B, Welsh PM, Wylie WA, Young SC, Martin H, Mahler J, Brady L, Wilkinson K (2002) PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J Med Chem 45:1221–1232

61. Pierce AC, Rao G, Bemis GW (2004) BREED: generating novel inhibitors through hybridization of known ligands application to CDK2, P38, and HIV protease. J Med Chem 47:2768–2775

62. Davies M, Heikkilä T, McConkey GA, Fishwick CW, Parsons MR, Johnson AP (2009) Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem 52:2683–2693

63. Jorgensen WL, Ruiz-Caro J, Tirado-Rives J, Basavapathruni A, Anderson KS, Hamilton AD (2006) Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 16:663–667

64. Schüller A, Suhartono M, Fechner U, Tanrikulu Y, Breitung S, Scheffer U, Göbel MW, Schneider G (2008) The concept of template-based de novo design from drug-derived molecular fragments and its application to TAR RNA. J Comput Aided Mol Des 22:59–68

65. Firth-Clark S, Kirton SB, Willems HM, Williams A (2008) De novo ligand design to partially flexible active sites: application of the ReFlex algorithm to carboxypeptidase A, acetylcholinesterase, and the estrogen receptor. J Chem Inf Model 48:296–305

66. Park H, Bahn YJ, Ryu SE (2009) Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors. Bioorg Med Chem Lett 19:4330–4334

67. Schneider G, Geppert T, Hartenfeller M, Reisen F, Klenner A, Reutlinger M, Hähnke V, Hiss JA, Zettl H, Keppner S, Spänkuch B, Schneider P (2011) Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors. Future Med Chem 3:415–424